Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 27, 2021

The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

Veriheal

APRIL 11, 2022

federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

SEPTEMBER 23, 2021

This Was the World’s First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction. It was the first published study assessing MDMA-Assisted Psychotherapy as a treatment for addiction. With a 20% relapse rate within the first nine months, compared to 75% relapse rate with traditional treatments.

Research and Development 52

Research and Development Therapy Treatment Data 52

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. Research published in 2016 revealed that 59% of a sample of patients who misused opioids were first exposed to them through a medical prescription.

Programs 52

Programs Chronic Pain Treatment Conditions 52

Cannabis Law Report

JANUARY 31, 2022

(TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. OTCQX trading.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

SpeedWeed

MARCH 14, 2021

Big data and technology have become critical to a wide variety of industries in recent years, and the cannabis industry is no exception. Through advanced data collection and the application of sophisticated algorithms, usable data is now available to help marijuana businesses: Predict trends. Met consumer demands. Reduce costs.

Data 52

Data Research and Development Marijuana Collective 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

MMJ Recs

MARCH 16, 2024

With increasing acceptance of medical marijuana as a legitimate treatment option for various health conditions, the industry has attracted significant attention from investors, entrepreneurs, and policymakers alike. Additionally, stigma and misinformation surrounding medical marijuana persist, impacting public perception and patient access.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.

Research and Development 105

Research and Development Data Conditions Therapy 105

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Cannabis Law Report

AUGUST 14, 2019

Let’s take a closer look at five key ways big data and technology are directly impacting the industry. Big Data Streamlines the Marijuana Regulatory Process and Helps Close the Scientific Research Gap. Big Data Improves Distribution in the Marijuana Industry. Source: [link]. Global Cannabis Applications Corp.

Data 45

Data Research and Development Marijuana Collective 45

Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

The Cannigma

MARCH 2, 2021

This issue is compounded when veterans do, on rare occasions, ask their doctors about medical marijuana, only to be treated as if they are mentally unstable or receive no specific health information at all,” the researchers found. This directly conflicts with past research claiming marijuana increases PTSD symptom severity.”.

Research and Development 143

Research and Development Treatment Chronic Pain Sleep 143

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Wesana is a serious, thoughtful and ethical company engaged in the development of psychedelic-assisted therapy. Like PTSD, TBI can have a profound impact on mental health.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc. About Cybin.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. By Brett Mulligan.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

JULY 20, 2021

With our new psychedelic medicinal insurance solutions, business can access the necessary coverages to protect their business, attract qualified officers/directors, and bring new treatments to market.”. Eric Rahn, Managing Director. As with any niche industry still in its infancy, the risks are high.

Medicine 98

Medicine Business Research and Development Chronic Pain 98

Cannabis Law Report

JULY 28, 2021

Andy served as University of Alberta Associate Vice President (Research) and was a member of the Scientific Advisory Board of the CIHR Institute of Neuroscience Mental Health & Addiction from 2012-2016. With his research and insight, Dr. Greenshaw has held many roles within the greater community.

Research and Development 105

Research and Development Events Media Data 105

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Program between St. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 9, 2021

Pavel Otáhal, contributing author and Head of the Gene Immunotherapy Research Department at ÚHKT, stated, “Our study compares the manufacture of CAR19 T-cells via PCR-made transposon DNA (LinearDNA) with mRNA encoding of the transposase against a conventional plasmid approach. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, who most recently served as CSO of Ardelyx, Inc., We’re thrilled to welcome Jeff to the Goldfinch Bio team.

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

SpeedWeed

AUGUST 11, 2021

According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

CannaMD

MAY 4, 2021

Similar technology has been successfully applied to facilitate decision-making in complex scenarios such as developing appraisal policies for disposal of nuclear waste. Translation? The scientific model employed in the present study is incredibly trustworthy! Before beginning their analysis, scientists identified 16 harm criteria.

Research and Development 105

Research and Development Data Marijuana Treatment 105

SpeedWeed

MAY 22, 2021

Over the next two months, researchers will evaluate whether the subjects experience increased self-compassion, professional burnout, or any other changes to their professional quality of life. Fortunately, MAPS has already conducted several clinical studies confirming that this treatment is both safe and effective.

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Cannabis Law Report

OCTOBER 29, 2021

Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. The Abstract is as follows. Introduction. diet, alcohol and tobacco consumption, and exercise) 11.

Research and Development 52

Research and Development Treatment Data Conditions 52

The Cannigma

MARCH 14, 2023

Laws restricting birth control, abortion, drug use, as well as requirements to receive welfare, drug treatment and even pain medication are developed in a paternalistic nature. Last year, I partnered with The Cannigma to dive deeper into the process of developing a medical cannabis identity. This is indeed what we found.

Policy 96

Policy Research and Development Conditions Consumption 96

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Dr. Tucker has successfully advanced several programs through clinical development and regulatory approval. CAMBRIDGE, Mass.–(BUSINESS Dr. Tucker. “I

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome. Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 1, 2021

While Wednesday’s $2 billion sales milestone does account for initial delivery sales conducted via the three operating licensees, the Commission is not parsing out specific data at this time to maintain driver safety. This past May, the Commission launched the license application for Marijuana Delivery Operators.

Marijuana 100

Marijuana Seed-To-Sale Safety Data 100

Cannabis Law Report

JULY 25, 2022

To become a registered patient with legal rights to purchase medical marijuana, a state-licensed physician must determine that you would indeed benefit from this treatment. Some of the conditions that qualify for receiving medical marijuana treatment in Pennsylvania include, but are not limited to: Muscle spasticity. Anxiety disorders.

Legalization 52

Legalization Marijuana Epilepsy Sativa 52

PrestoDoctor

SEPTEMBER 6, 2023

Many individuals are becoming more cautious about the long-term use of prescription pain medications due to concerns about dependency and the risk of developing opioid use disorder. Pain Management : Research published in the European Journal of Pain in 2018 examined the effects of combining cannabis and opioids for pain management.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105